Brain Blogger Home
  • Home
  • About
    • Editor's Note
    • Contributors
  • Advertise
  • Archives
    • By Author
    • By Topic
    • By Year
    • By Month
  • Contact
  • Contribute
  • Topics
    • Popular
    • Series
    • Video
    • Carnivals
  • Sitemap
  • Subscribe
  • Neuroscience & Neurology
  • Psychology & Psychiatry
  • Health & Healthcare
  • More >>
    • BioPsychoSocial Health
    • Complementary & Alternative Medicine
    • Drugs & Clinical Trials
    • History of Medicine
    • Law & Politics
    • Living with a Brain Disorder
    • Opinion
    • Site News
    • Stigmatization
Brain Blogger RSS Feed

Brain Blogger Feed - 3500+ Readers

Follow BB:

Brain Blogger on FaceBook Brain Blogger on twitter Brain Blogger on Flickr Brain Blogger on YouTube
Drugs & Clinical Trials
December 9, 2008

Beating the Biological Clock – Clinical Trials of Tasimelteon

By Sajid Surve, DO | 1 Comment | Share | Print | Email | Tweet | Like | 1+

The Lancet recently published clinical trial data from a Harvard study which compares the experimental new drug tasimelteon to placebo in treating jet lag. The medication works by binding to the same receptor as melatonin, and activating it as a direct agonist.

Melatonin is a neurotransmitter produced by the brain that is believed to play a pivotal role in the regulation of our “biological clock” or circadian rhythm. Melatonin levels fluctuate in the bloodstream throughout the day, and surge during the nighttime hours when it is dark outside and our bodies are inclined to sleep. The trouble with melatonin is that it falls under the FDA category of supplements and nutraceuticals, and is therefore largely unregulated in terms of potency, manufacturing process, and quality of ingredients. Studies are hard to conduct and successfully repeat for this reason as well.

SleepTasimelteon was studied in a multicenter, randomized, placebo-controlled clinical trial for its phase III testing. The study recruited 411 healthy volunteers aged 21-50, who were randomized to receive either a placebo, or tasimelteon at 20 mg, 50 mg, or 100 mg. The volunteers were observed in a sleep clinic for 7 nights. The first 3 nights they went to sleep at their normal bedtime and did not receive any medication. Measurements were taken regarding the time to fall asleep, quality of sleep, and duration of sleep before waking. For the next 3 nights, the volunteers attempted to fall asleep 5 hours prior to their established bedtime to simulate jet lag, and were given their respective medication/placebo dose 30 minutes prior to their attempt. The same measurements were taken. On the 7th day, volunteers returned to their established bedtime but also received their medication/placebo 30 minutes prior. Measurements again were taken.

The results of the trial were that subjects who received tasimelteon fell asleep quicker, had a deeper and more efficient quality of sleep, and slept longer than subjects who received the placebo. The benefits were also dose-dependent, meaning the benefits improved as the dosage went from 20 mg to 50 mg to 100 mg. Side effect profiles were similar to placebo across all groups. Given this strong phase III data, the medication may be approved by the FDA and available to the public within the next 2-3 years.

Two to three years may be too long for airline pilots, shift workers, or any other frequent travelers who deal with jet lag on a regular basis. Current options for the management of jet lag are lackluster. Benzodiazepines are the main option, can be habit-forming, and have several untoward side effects. Hypnotics are also habit-forming, and must be timed appropriately because one cannot operate machinery or drive for several hours after being taken. Melatonin has no conclusive clinical data proving that it works, and as mentioned above, obtaining a quality product can be difficult. A medication like tasimelteon would be a welcome addition as it appears to have very few side effects, is not habit-forming, and works by altering circadian rhythms to allow a patient to fall asleep and stay asleep naturally.

Reference

S RAJARATNAM, M POLYMEROPOULOS, D FISHER, T ROTH, C SCOTT, G BIRZNIEKS, E KLERMAN (2008). Melatonin agonist tasimelteon (VEC-162) for transient insomnia after sleep-time shift: two randomised controlled multicentre trials The Lancet DOI: 10.1016/S0140-6736(08)61812-7

Sajid Surve, DO

Dr. Surve is a physiatrist, acupuncturist, and osteopath who specializes in musculoskeletal medicine and integrative medicine.

Related Articles

  • Sleeping on the Job – A Program Director’s Take on IOM Recommendations
  • Sleep and Consciousness – A Dynamic State of Being
  • Ambien, Sonata, and Lunesta – The Morning After
  • The Sad Implications of Sunday Sleep Problems
  • Sleep Deprivation, Behavior, and the Young
  • Sleep Disorders Demystified
  • Colic and Probiotics – A Cure for the Crying?

1 Response

    1. Tasimelteon - Diabetes Forums says:
      December 9, 2008 at 3:21 pm

      [...] case, long distance travel would create a critical situation as my body adjusted to new rythms. Beating the Biological Clock – Clinical Trials of Tasimelteon | Brain Blogger Beating the Biological Clock – Clinical Trials of Tasimelteon The Lancet recently published [...]

      Reply

    Leave a Reply

    Click here to cancel reply.

    Subscribe without commenting


    Popular Posts

    • The Love Drug
    • Women After Sex
    • Fatty Acids and Suicide Risk
    • Mind Games - Science's Attempts at Thought Control
    • Risks of Personalized Medicine
    • Mental Health Disorders Prevalent Among Youth Worldwide
    • Is Giftedness Nothing More than Good Genes?
    • The Many Emerging Roles of Astrocytes
    • Behind the Masks - The Mysteries of Dissociative Identity Disorder
    • The NeuroSocial Network

    Future Posts

    • The Brain’s Buying Power

    Latest Posts

    • Aging Intelligently
    • A Nicotine Patch a Day Keeps the Cognitive Impairment Away
    • The Many Emerging Roles of Astrocytes
    • Diabetes Impairs Cognition
    • Media Violence Leads to Real Violence
    • Intelligence – Are You Holding Back Your Brain?
    • Childhood Aggression Predicts Health Care Use Later in Life
    • The Brain’s Border Patrol – Blood Brain Barrier
    • Risks of Personalized Medicine
    • BED-head and Obesity – Food for Thought

    Comments

    • : This article had great info on
    • peter: I also see things the same way
    • Scapadas Amorosas: Lets patent it, package, marke
    • Emily Haines, MSc, PhD student: Thanks for your comments, Matt
    • Emily Haines, MSc, PhD student: Thanks for your comments and s
    • Alex: While we have our eyes glued t
    • Richard Kensinger, MSW: Carla,You are absolutely c
    • Soraya L. Valles: I'm interested in astrocytes.
    • Raymond Tallis: Dear Kitty, I have come to you
    • Steven: After smoking for 17 years dai
    • Matt: I'm just interested in hearing
    • Carla Easley: If everyone adopted the "Growt
    Sponsored Links

    GNLD, memory improvement, web design brisbane, Autism News Blog, Pharmaceutical Training, Neurotherapist, HGH, Rollup Banner Stands , Buy Advair Diskus Online , Atomic PR , drug rehab , Lab Tests Pennsylvania

    Copyright © 2005-2012 Brain Blogger sponsored by Global Neuroscience Initiative Foundation (GNIF). All Rights Reserved.
    Disclaimer | Privacy Policy | Feed | Log in | ISSN 1931-6224 | 3.899s
    9rules Network Member